(201 days)
K#974399
K#974399
No
The description focuses solely on the material composition and physical properties of a collagen-based bone filling material. There is no mention of software, algorithms, data processing, or any other elements typically associated with AI/ML in medical devices.
No.
The device is a collagen-based bone filling augmentation material intended for filling extraction sockets and oral maxillofacial defects, which categorizes it as a surgical/dental material rather than a device that provides therapeutic treatment to a living body (e.g., pain relief, disease treatment, or rehabilitation).
No
The device is described as a "collagen-based bone filling augmentation material" and a "bone filling material for dental bone defects," indicating its use for treatment or augmentation, not diagnosis.
No
The device is described as a physical, collagen-based bone filling material, not software.
Based on the provided information, the FOUNDATION device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to fill extraction sockets and oral maxillofacial defects. This is a therapeutic or restorative use, not a diagnostic one.
- Device Description: The device is a collagen-based bone filling material. It is designed to be implanted or placed in the body to aid in bone regeneration. This is characteristic of a medical device used for treatment or repair.
- Lack of Diagnostic Function: There is no mention of the device being used to test a sample from the human body (like blood, urine, tissue, etc.) to provide information about a disease or condition.
IVD devices are specifically designed to perform tests on samples taken from the body to diagnose, monitor, or screen for diseases or conditions. The FOUNDATION device's function is to physically fill a void and promote healing, which falls under the category of a medical device for treatment.
N/A
Intended Use / Indications for Use
The FOUNDATION device is a collagen-based bone filling augmentation material for use in the filling of extraction sockets.
The FOUNDATION device is a collagen-based bone filling augmentation matcrial for use in the filling of extraction sockets with oral maxillofacial defects.
Product codes
LYC
Device Description
The FOUNDATION device is a sponge-like absorbable natural collagen plug designed to be used as a bone filling material for dental bone defects. The device consists of approximately 85-95% Type I collagen and approximately 5-15% Type III collagen from bovine dermis collagen sources in the United States.
The FOUNDATION device is manufactured in both bullet-shape and in sheets. The device comes in a heat-sealed aluminum package.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
oral maxillofacial
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K#974399
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 872.3930 Bone grafting material.
(a)
Identification. Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.(b)
Classification. (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image is a black and white emblem. The emblem is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES.USA" around the perimeter of the circle. Inside the circle is a symbol that appears to be three stylized human profiles facing to the right.
NOV - 8 2004
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr Keith Barritt. Esq Fish and Richardson, P.C. 1425 K Street, N. W. Washington, D. C. 20005
Re: K040783
Trade/Device Name: FOUNDATION Wound Covering Material Regulation Name: Bone Void Filler Regulatory Class: Unclassified Product Code: LYC Dated: March 25, 2004 Received: March 26, 2004
Dear Mr. Barritt:
This letter corrects our substantially equivalent letter of October 13, 2004. regarding FDA's clearance of K040783, using a version of the FQUNDATION Indications for Use Statement that was not the latest revision of that statement. The correct Indications for Use Statement is enclosed.
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent for use in filling extraction sockets, to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Page 2 - Mr. Barritt
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours.
Ques
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/0 description: The image shows a handwritten string of characters. The characters are 'K040783'. The characters are written in black ink on a white background. The handwriting is somewhat stylized.
510(k) Number (if known): Device Name: FOUNDATION Bone Filling Augmentation Material Indications For Use:
The FOUNDATION device is a collagen-based bone filling augmentation material for use in the filling of extraction sockets.
(DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription User
OR
Over-The-Counter Use
(Per 21 CFR 801.109)
Suver Ruane
(Division Sign-Off) Division of Anesthesiology, General Hospital, Infection Control, Dental I
510(k) Number: K040783
40223476.doc
3
510(k) SUMMARY
007 1 3 2004
Terumo Corporation FOUNDATION Bone Filling Augmentation Material 510(k) Premarket Notification
Name of Device and Name/Address of Sponsor
Trade or Proprictary Name: FOUNDATION
Common Name: wound covering material
Classification Name: bone filling augmentation material
Product Code : LYC (unclassified)
Terumo Corporation 44-1, 2 chome Hatagaya, Shibuya-ku Tokyo 151-0072 Japan
Contact Person: Mr. Yoshiaki Nagura Date Prepared: May 26, 2003
Intended Use
The FOUNDATION device is a collagen-based bone filling augmentation matcrial for use in the filling of extraction sockets with oral maxillofacial defects.
Technological Characteristics and Substantial Equivalence
The FOUNDATION device is a sponge-like absorbable natural collagen plug designed to be used as a bone filling material for dental bone defects. The device consists of approximately 85-95% Type I collagen and approximately 5-15% Type III collagen from bovine dermis collagen sources in the United States.
The FOUNDATION device is manufactured in both bullet-shape and in sheets. The device comes in a heat-sealed aluminum package.
Exhibit 36 Page 1 of 2
4
Atelocollagen (pepsin solubilized collagen) is purchased from a raw material supplier. Testing is performed to ensure that the telo-peptide has been removed. Protein, excluding collagen, and fat are removed during the extraction process from bovine dermis to atelocollagen at the raw materials supplier's facility. To control antigenicity throughout the manufacturing process, tyrosine moiety is controlled at less than 3/1000. All of the manufacturing of the FOUNDATION device takes place in a "clean room."
The FOUNDATION device is packaged into individual packages and heat-sealed. Quality testing before shipping is performed on the finished devices. The product is physically tested for appearance. Cross-linking is verified by testing to ensure the product maintains its operating characteristics. Sterility tests are also performed.
The FOUNDATION device was approved by the Japanese Ministry of Health, Welfare and Labor as the TERUPLUG on July 7, 1997 for the following indications: (1) to stop bleeding after an odontectomy; (2) to cover the surface of a wound created by an odontectomy to prevent contamination and infection of the wound; (3) to accelerate granulation formation at the site of the odontectomy; and (4) to relieve pain at the wound site duc to wound coverage.
The FOUNDATION device is substantially equivalent for purposes of the FDA 's medical device regulations to BIO-OSS COLLAGEN, which is approved for the filling of extraction sockets to enhance the preservation of the alveolar ridge (K#974399). The FOUNDATION device has the same gencral intended use, similar principles of operation, and similar technological characteristics as the previously cleared predicate device. Although there are some difference in the characteristics of the FOUNDATION device and the predicate device, such as sponge configuration vs. granular configuration, these differences do not raise new questions of safety or efficacy.
4()146081.doc